Myelodysplastic syndrome in a 30-year-old man with coronavirus disease 2019 (COVID-19): a diagnostic challenge.
Bone Marrow
COVID-19
Cytogenetics
Myelodysplastic Syndromes
SARS-CoV-2
Journal
Autopsy & case reports
ISSN: 2236-1960
Titre abrégé: Autops Case Rep
Pays: Brazil
ID NLM: 101640070
Informations de publication
Date de publication:
20 Apr 2021
20 Apr 2021
Historique:
entrez:
10
5
2021
pubmed:
11
5
2021
medline:
11
5
2021
Statut:
epublish
Résumé
Myelodysplastic syndromes (MDS) mainly occur in the elderly but can rarely affect younger individuals too. The correct diagnosis relies on careful morphologic evaluation, cytogenetic/molecular results, and excluding reactive conditions mimicking MDS. We present the clinical, pathologic, cytogenetic, and molecular features of a case of MDS with excess blasts-2 (MDS-EB-2) in a 30-year-old male who was found to have pancytopenia during his hospitalization for coronavirus disease 2019 (COVID-19) and discuss the diagnostic challenges of MDS in patients with COVID-19. A 30-year-old man presented to an outside hospital with fever, chills, weakness, coughing spells, dizziness and shortness of breath and was diagnosed with bilateral pneumonia due to COVID-19. At the outside hospital, he was found to be pancytopenic, and a subsequent bone marrow aspiration and biopsy raised concern for a COVID-19 induced hemophagocytic lymphohistiocytosis. In addition, MDS could not be ruled out. The patient was thus referred to our institute for further management. The patient's peripheral blood showed pancytopenia with occasional dysplastic neutrophils and a few teardrop cells. Given the diagnostic uncertainty, a bone marrow aspiration and a biopsy were repeated revealing a hypercellular bone marrow with erythroid hyperplasia, megakaryocytic hyperplasia, trilineage dysplasia, increased blasts (13%), many ring sideroblasts, and mild to moderate myelofibrosis, consistent with MDS-EB-2. Chromosomal analysis revealed isochromosome 14. Next generation sequencing demonstrated SF3B1 K700E mutation. The diagnosis of MDS can be challenging, particularly in young patients. Cytopenia and myelodysplastic features have been reported in COVID-19 patients, making the diagnosis of MDS more elusive. A careful pathologic examination of the bone marrow with ancillary studies including flow cytometry, immunohistochemistry, and cytogenetic and molecular studies in combination with a thorough clinical evaluation, leads to the accurate diagnosis.
Sections du résumé
BACKGROUND
BACKGROUND
Myelodysplastic syndromes (MDS) mainly occur in the elderly but can rarely affect younger individuals too. The correct diagnosis relies on careful morphologic evaluation, cytogenetic/molecular results, and excluding reactive conditions mimicking MDS. We present the clinical, pathologic, cytogenetic, and molecular features of a case of MDS with excess blasts-2 (MDS-EB-2) in a 30-year-old male who was found to have pancytopenia during his hospitalization for coronavirus disease 2019 (COVID-19) and discuss the diagnostic challenges of MDS in patients with COVID-19.
CASE PRESENTATION
METHODS
A 30-year-old man presented to an outside hospital with fever, chills, weakness, coughing spells, dizziness and shortness of breath and was diagnosed with bilateral pneumonia due to COVID-19. At the outside hospital, he was found to be pancytopenic, and a subsequent bone marrow aspiration and biopsy raised concern for a COVID-19 induced hemophagocytic lymphohistiocytosis. In addition, MDS could not be ruled out. The patient was thus referred to our institute for further management. The patient's peripheral blood showed pancytopenia with occasional dysplastic neutrophils and a few teardrop cells. Given the diagnostic uncertainty, a bone marrow aspiration and a biopsy were repeated revealing a hypercellular bone marrow with erythroid hyperplasia, megakaryocytic hyperplasia, trilineage dysplasia, increased blasts (13%), many ring sideroblasts, and mild to moderate myelofibrosis, consistent with MDS-EB-2. Chromosomal analysis revealed isochromosome 14. Next generation sequencing demonstrated SF3B1 K700E mutation.
DISCUSSION AND CONCLUSION
CONCLUSIONS
The diagnosis of MDS can be challenging, particularly in young patients. Cytopenia and myelodysplastic features have been reported in COVID-19 patients, making the diagnosis of MDS more elusive. A careful pathologic examination of the bone marrow with ancillary studies including flow cytometry, immunohistochemistry, and cytogenetic and molecular studies in combination with a thorough clinical evaluation, leads to the accurate diagnosis.
Identifiants
pubmed: 33968834
doi: 10.4322/acr.2021.274
pii: acrep095320
pmc: PMC8087351
doi:
Types de publication
Case Reports
Langues
eng
Pagination
e2021274Informations de copyright
Copyright: © 2021 The Authors.
Déclaration de conflit d'intérêts
Conflict of interest: None.
Références
Br J Haematol. 2009 Mar;144(5):800-2
pubmed: 19055669
Nat Genet. 2012 May 06;44(6):642-50
pubmed: 22561516
Pathobiology. 2019;86(1):7-13
pubmed: 30041243
Br J Haematol. 1996 Jul;94(1):206-9
pubmed: 8757536
Travel Med Infect Dis. 2020 Mar - Apr;34:101623
pubmed: 32179124
Curr Hematol Malig Rep. 2012 Dec;7(4):310-20
pubmed: 23015360
Am J Clin Pathol. 2020 Aug 5;154(3):319-329
pubmed: 32756872
Lancet. 2020 Feb 15;395(10223):497-506
pubmed: 31986264
EJHaem. 2020 Jun 29;:
pubmed: 32838398
J Biomed Biotechnol. 2010;2010:365318
pubmed: 21331167
Haematologica. 2012 May;97(5):723-30
pubmed: 22180437
Nat Genet. 2012 Nov;44(11):1179-81
pubmed: 23001125
Leukemia. 2015 Jan;29(1):66-75
pubmed: 24935723
Am J Hematol. 2020 Jul;95(7):870-872
pubmed: 32279346
Br J Haematol. 2006 Jul;134(1):95-9
pubmed: 16803574
Nat Genet. 2012 May 06;44(6):651-8
pubmed: 22561519
Blood. 2008 Jul 1;112(1):45-52
pubmed: 18443215
Turk J Haematol. 2020 Jun 26;37(4):310-302
pubmed: 32586086
Lancet. 2020 Feb 15;395(10223):507-513
pubmed: 32007143
Mediterr J Hematol Infect Dis. 2015 May 01;7(1):e2015034
pubmed: 25960862
Cancer. 2007 Apr 15;109(8):1536-42
pubmed: 17345612
Mod Pathol. 2020 Nov;33(11):2139-2146
pubmed: 32620916